



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 18, 2022

Mark Dybul
Chief Executive Officer
Enochian Biosciences Inc.
2080 Century Park East, Suite 906
Los Angeles, CA 90067

Re: Enochian Biosciences Inc.
Registration Statement on Form S-3
Filed February 11, 2022
File No. 333-262673

Dear Mr. Dybul:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Clayton E. Parker, Esq.